Early outcomes of thrombolysis for acute ischaemic  stroke in a South African tertiary care centre by Wasserman, Sean & Bryer, Alan
RESEARCH
541  June 2012, Vol. 102, No. 6  SAMJ
Stroke is an important cause of death and disability in sub-Saharan 
Africa, where it was estimated that 355 000 stroke deaths occurred 
in 2001,1 with a similar age-specific prevalence to developed 
countries,2 but resulting in much higher levels of disability.3 
Cerebrovascular disease is a growing problem in South Africa,4 
and places a heavy burden on family carers in poor socioeconomic 
environments.5 
Thrombolysis with recombinant tissue plasminogen activator (tPA, 
alteplase) is the only effective specific treatment for acute ischaemic 
stroke. The landmark National Institute of Neurological Disorders 
and Stroke (NINDS) rt-PA trial6 in the USA in 1995 demonstrated 
that patients receiving this intervention were 30% more likely 
to survive with minimal disability resulting in a 12% absolute 
increase in the proportion having excellent functional outcomes 
at 3 months. The benefits of thrombolysis have been consistently 
reproduced when used in routine clinical practice across different 
patient populations.7-9 Although its use increases rates of intracranial 
haemorrhage, thrombolysis has no impact on overall mortality.10
Net benefit can be achieved if tPA is administered within 4.5 hours 
of onset of stroke symptoms.11 This narrow window of opportunity 
represents the largest obstacle to more widespread use because of 
inefficient public transport systems and low levels of awareness 
about stroke.12 This and other issues, such as cost and the availability 
of resources required to administer this treatment, have caused 
concerns that thrombolysis may not be a viable option for treating 
stroke in developing countries. However, there is growing evidence of 
of its comparable efficacy and safety when used in these settings.13-17
The new South African national stroke guidelines recommend 
tPA as treatment for acute ischaemic stroke within 4.5 hours of 
symptom onset.18 However, there are no published data on the use of 
thrombolysis in Africa. We aimed to evaluate the early outcomes and 
safety of this intervention in a South African setting. 
Methods
This was a prospective, open, observational study of all patients 
receiving tPA for acute ischaemic stroke at Groote Schuur Hospital 
(GSH) from the year 2000. The hospital has a comprehensive stroke 
unit as defined by the national stroke guidelines.  
Patient eligibility was defined by the Stroke Unit protocol and 
included patients with a clinical diagnosis of acute stroke in whom it 
was ascertained that the time of onset of stroke symptoms was within 
3 hours of receiving thrombolysis. After publication of the ECASS III 
trial19 in 2008 this time window was extended to 4.5 hours. Exclusion 
criteria were based on the NINDS rt-PA trial6 protocol (in our study 
the upper age limit was 75 years), which broadly restricts eligibility 
to those without evidence of intracranial blood on baseline computed 
tomography (CT) scanning, low risk of bleeding, and those without 
rapidly resolving symptoms or severe neurological deficit (National 
Institutes of Health stroke scale (NIHSS) >25). 
Baseline and demographic characteristics, stroke type and severity, 
time intervals, risk factors, and medication history were recorded. 
Neurological impairment and functional disability were assessed 
on arrival and at discharge using the NIHSS score and the modified 
Rankin scale (mRS), respectively. CT scans were performed at 
baseline and within 36 hours of thrombolysis, or on evidence of 
clinical deterioration.
The primary outcome measure was the proportion of patients 
achieving significant early neurological recovery defined as an 
improvement of 4 or more points on the NIHSS score at discharge. 
The safety endpoint was the rate of symptomatic intracranial 
haemorrhage (SICH) and death. SICH was defined according to 
the NINDS rt-PA/Cochrane criteria6,20 as any new evidence of 
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intracranial blood on CT or magnetic resonance imaging (MRI) 
accompanied by a neurological deterioration of 4 or more points 
on the NIHSS score from baseline. Functional independence (i.e. an 
mRS score of 0 - 2) or an improvement of two or more points on the 
mRS achieved at discharge were secondary outcomes. 
The proportion of patients with SICH, mortality, independence, 
and neurological improvement were calculated and compared with the 
corresponding proportions in the alteplase arm of the NINDS rt-PA 
and ECASS III trials, and with observational studies in developed and 
other developing countries.
Demographic profiles were compared with a cohort of unmatched 
patients who suffered ischaemic strokes but who were managed 
conservatively in our stroke unit. The latter patients were ineligible 
for thrombolysis, and their data were recorded in the same register as 
those who received tPA from January 2000 to April 2006. 
Written informed consent was obtained either from the patients 
or from a close family member. Alteplase was administered in 
consultation with the attending neurologist or stroke physician. An 
intravenous (IV) dose of alteplase (0.9 mg/kg, with 10% given as a 
bolus followed by an infusion over 1 hour) was administered in the 
emergency department after the baseline CT scan was reviewed. 
Selected patients received intra-arterial (IA) alteplase.
This study was approved by the UCT-GSH Human Research Ethics 
Committee (Ref: 386/2011). 
Results
Forty-two patients were thrombolysed at GSH from January 2000 to 
February 2011. Their mean age was 60 (SD 12.26, range 24 - 79) and 
the median baseline NIHSS score was 14 (interquartile range (IQR) 
10.5 - 17). Approximately 60% were clinically assessed to have large-
vessel atheroembolic aetiologies. Thirty-six (85.7%) received IV tPA, 
4 (9.5%) received IA tPA and 2 (4.8%) received bridging treatment 
with IV tPA followed by an endovascular procedure including IA tPA. 
Three (7.1%) patients were over the age of 75 years.  
Table 1 shows clinical data, including stroke type and severity. 
NIHSS data were complete at discharge in 39 (93%) patients and the 
mRS was recorded for all patients. The mean time to tPA infusion was 
160 minutes (SD 50, range 60 - 270). Most patients (29, 72.5%) were 
thrombolysed within 180 minutes. Median duration of hospital stay 
was 12 days (IQR 8 - 15.8). Table 2 compares demographic data of the 
patients receiving tPA, and unmatched patients with acute ischaemic 
stroke managed conservatively in the same unit. Of the patients who 
received thrombolysis, 25/42 (59.5%) arrived at hospital using their 
own transport; the next most common referral source was from 
private hospitals (5/42, 11.9%) (Fig.1).
Fig. 2 illustrates early neurological outcomes grouped by severity. 
Table 1. Baseline clinical characteristics of patients receiving 
tPA (N=42)
Variable
Age (years), median (IQR) 62 (52 - 67.5)
Male sex, % 54.8
Married, n (%) 24 (57.1)
Systolic blood pressure (mmHg), median (IQR) 149 (134 - 170)
Diastolic blood pressure (mmHg), median (IQR) 84 (76 - 90)
Degree of neurological severity (NIHSS) 14 (10.5 - 17)
Mild (0 - 7), n (%) 2 (4.8)
Moderate (8 - 14), n (%) 19 (45.2)
Severe (≥15), n (%) 18 (42.9)
Cause of stroke
Large-vessel atheroembolic, n (%) 25 (59.5)
Lacunar, n (%) 3 (7.1)
Cardioembolic, n (%) 9 (21.4)
Other, n (%) 3 (7.1)
Unknown, n (%) 2 (4.8)
Stroke onset to treatment time (min), 
mean (SD) 160 (±50)
Table 2. Demographic characteristics of patients receiving 
tPA compared with unmatched patients with acute 






School (years), median (IQR) 10 (8.5 - 12) 8 (6 - 10)
Tertiary, n (%) 6 (14.3) 57 (6.5)
Income    
Employed, n (%) 17 (40.5) 228 (25.9)
Grant, n (%) 20 (47.6) 432 (49)
Housing    
House, n (%) 41 (97.6) 736 (83.4)
Shack, n (%) 1 (2.4) 96 (10.8)
Fig. 1. Referral sources of patients receiving tissue plasminogen activator 
(tPA) and those managed conservatively.
Fig. 2. Early neurological outcomes grouped by severity (mild = NIHSS 0 - 7; 
moderate = NIHSS 8 - 14; severe = NIHSS ≥15).
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The median NIHSS score fell to 7.5 (IQR 1 - 15) by the time of 
discharge. Forty-eight per cent of patients scored in the mild range 
(0 - 7), compared with only 5% on arrival. At discharge 18 (42.9%) 
patients had improved their mRS by 2 or more points and 17 (40.5%) 
were functionally independent. Over half (53.8%) of our patients 
were discharged home. Fig. 3 compares the proportion of patients 
who achieved significant neurological improvement in this study 
with that of other studies. 
Fig. 4 compares our patients and results from other studies for 
SICH (using the NINDS rt-PA/Cochrane definition) and mortality. 
Only 2 (4.8%) of our patients suffered SICH. Adverse effects were 
not significantly related to time of tPA infusion, age or stroke severity. 
All three patients aged >75 years experienced bleeding complications 
with one, aged 76, suffering a symptomatic intracranial haemorrhage 
(NIHSS 8). Another, aged 79, had an asymptomatic intracranial 
haemorrhage (NIHSS 28), and the third patient, aged 78, developed a 
femoral haematoma (NIHSS 19). 
At the time of discharge a total of 3 (7.1%) patients had died, all of 
whom had admission Rankin scores of 5. Besides the single patient 
with fatal intracranial haemorrhage the deaths were unrelated to 
treatment; one patient died of an acute myocardial infarction, and the 
other from an additional cerebral infarct and nosocomial pneumonia. 
Discussion
Two-thirds of our patients achieved significant neurological 
improvement after receiving tPA, which compares favourably with the 
NINDS rt-PA trial.6 Smaller studies from other developing countries 
reported similar results.13-17 The European Medicines Evaluation 
Agency allowed registration of tPA for acute stroke in 2002, on 
condition that an observational safety study be performed to address 
concerns about the applicability of data from randomised controlled 
trials to individuals in daily clinical practice. At 3-month follow-
up, 54.8% of patients in this SITS-MOST cohort were functionally 
independent,7 compared with 40.5% at the time of discharge in 
our study. Although other studies demonstrated sustained clinical 
benefit of thrombolysis,20 this could not be assessed with our study 
design which was limited by a short follow-up period. However, the 
functional outcomes of our patients may be comparable with those 
of the SITS-MOST study as improvement after tPA typically occurs 
early because of vessel recanalisation, and further recovery would be 
anticipated in our surviving patients with rehabilitation in the 90 days 
post discharge.
Our patients had a lower rate of SICH compared with the NINDS 
rt-PA trial (4.8% v. 6.4%)6 and the large open-label SITS-ISTR study 
(8.0% for patients treated between 3 and 4.5 hours and 7.3% for 
patients treated within 3 hours).9 Pooled data from five observational 
studies from developing countries show a lower proportion of 
patients suffering SICH, 9/293 (3.1%), but the rates ranged from 0 
to 5.9% between the different centres.13-17 Although the number is 
small and does not represent a significant association, all three of 
our patients over the age of 75 had bleeding complications. Studies 
in the developed world support the safety of tPA in patients over 80 
years.21 However, more caution may be needed in our setting when 
thrombolysing elderly patients.
Our in-patient mortality was similar to that of the NINDS rt-PA 
trial (7.4%), but could not be compared with large observational 
studies such as SITS-MOST and CASES as these only reported 
3-month mortality rates. The 7-day mortality of 11 621 patients 
treated within 3 hours in routine practice across Europe was similar 
to ours at 6.5%; the rate for those treated between 3 and 4.5 hours in 
the same registry was 7.5%.9 In 3 studies from developing countries 
the mortality at discharge ranged from 0 to 5.9%.13,14,16
It is estimated that <2% of patients with ischaemic stroke in our 
hospital drainage area received thrombolysis, which seems comparable 
with data from other developing countries.15,16 However, our reported 
thrombolysis rate is an overestimation for the general population, as 
most patients with acute stroke are managed conservatively at lower 
level facilities where thrombolysis is not available.
This study was not designed to identify barriers to accessing 
thrombolysis, but inferences may be drawn from our findings in this 
regard. Most patients who qualified for tPA used their own transport 
to hospital, suggesting that delays in the emergency medical services 
transport system may be a cause for arrival outside of the 4.5 hour 
window period. A greater proportion of patients who received 
thrombolysis were employed, and lived in brick houses compared 
with conservatively managed patients, suggesting that those with 
higher incomes are more likely to arrive at hospital within the narrow 
time window required for this intervention. As in other studies,10,12 
low levels of public awareness of stroke may be another barrier to 
thrombolysis in our setting as reflected by the difference in education 
levels between the patient groups. Certain quarters in South Africa’s 
emergency medicine community22 and elsewhere are reluctant to 
use tPA for stroke,23 and this may also have contributed to the small 
numbers of patients referred from secondary level hospitals. 
A study limitation is the relatively small number of patients with 
ischaemic stroke in the GSH cohort that received tPA. Nevertheless, 
the data indicate that the use of thrombolysis in routine clinical 
practice in a South African setting has similar safety and early 
efficacy outcomes to developed and other developing countries. 
Thrombolysis is specialised and is not available to most South 
Africans. However, its benefits for reducing disability for stroke 
Fig. 4. Proportion of patients with symptomatic intracranial haemorrhage 
and mortality in the GSH cohort and other trials,6,19 as well as observational 
studies.7-9,13-17 SICH = symptomatic intracranial haemorrhage. Percentages 
in red = 3-month data, in black = data at discharge. 
Fig. 3. Proportion of patients achieving early neurological improvement 
(NIHSS ≥4 points) compared with other studies.6,13,14,16 
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victims should be promoted in the lay and medical community. 
Implementing an acute stroke response network in the emergency 
services must be considered to facilitate early arrival and assessment 
at a designated stroke centre where thrombolysis is available.
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